353 related articles for article (PubMed ID: 33350463)
1. Deciphering the role of epigenetic modifications in fatty liver disease: A systematic review.
Zhang X; Asllanaj E; Amiri M; Portilla-Fernandez E; Bramer WM; Nano J; Voortman T; Pan Q; Ghanbari M
Eur J Clin Invest; 2021 May; 51(5):e13479. PubMed ID: 33350463
[TBL] [Abstract][Full Text] [Related]
2. Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease.
Li YY
World J Gastroenterol; 2012 Dec; 18(45):6546-51. PubMed ID: 23236228
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic Regulation in Lean Nonalcoholic Fatty Liver Disease.
Aggeletopoulou I; Kalafateli M; Tsounis EP; Triantos C
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629043
[TBL] [Abstract][Full Text] [Related]
4. Noncoding RNAs in Nonalcoholic Fatty Liver Disease: Potential Diagnosis and Prognosis Biomarkers.
Khalifa O; Errafii K; Al-Akl NS; Arredouani A
Dis Markers; 2020; 2020():8822859. PubMed ID: 33133304
[TBL] [Abstract][Full Text] [Related]
5. Epigenetics in non-alcoholic fatty liver disease.
Lee J; Kim Y; Friso S; Choi SW
Mol Aspects Med; 2017 Apr; 54():78-88. PubMed ID: 27889327
[TBL] [Abstract][Full Text] [Related]
6. Histone Modifications in NAFLD: Mechanisms and Potential Therapy.
Shi Y; Qi W
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834101
[TBL] [Abstract][Full Text] [Related]
7. The Role of Epigenetics in the Progression of Non-Alcoholic Fatty Liver Disease.
Aguilar-Olivos NE; Oria-Hernández J; Ponciano-Rodríguez G; Chávez-Tapia NC; Uribe M; Méndez-Sánchez N
Mini Rev Med Chem; 2015; 15(14):1187-94. PubMed ID: 26156419
[TBL] [Abstract][Full Text] [Related]
8. Potential epigenetic mechanism in non-alcoholic Fatty liver disease.
Sun C; Fan JG; Qiao L
Int J Mol Sci; 2015 Mar; 16(3):5161-79. PubMed ID: 25751727
[TBL] [Abstract][Full Text] [Related]
9. Epigenetics factors in nonalcoholic fatty liver disease.
Pirola CJ; Sookoian S
Expert Rev Gastroenterol Hepatol; 2022 Jun; 16(6):521-536. PubMed ID: 32476509
[No Abstract] [Full Text] [Related]
10. Noncoding RNAs as additional mediators of epigenetic regulation in nonalcoholic fatty liver disease.
Zaiou M
World J Gastroenterol; 2022 Sep; 28(35):5111-5128. PubMed ID: 36188722
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome Proliferator-Activated Receptor-γ as a Target and Regulator of Epigenetic Mechanisms in Nonalcoholic Fatty Liver Disease.
Zaiou M
Cells; 2023 Apr; 12(8):. PubMed ID: 37190114
[TBL] [Abstract][Full Text] [Related]
12. DNA Methylation in Nonalcoholic Fatty Liver Disease.
Hyun J; Jung Y
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33143364
[TBL] [Abstract][Full Text] [Related]
13. Epigenome-Wide Association Study Identifies Methylation Sites Associated With Liver Enzymes and Hepatic Steatosis.
Nano J; Ghanbari M; Wang W; de Vries PS; Dhana K; Muka T; Uitterlinden AG; van Meurs JBJ; Hofman A; ; Franco OH; Pan Q; Murad SD; Dehghan A
Gastroenterology; 2017 Oct; 153(4):1096-1106.e2. PubMed ID: 28624579
[TBL] [Abstract][Full Text] [Related]
14. The role of global and regional DNA methylation and histone modifications in glycemic traits and type 2 diabetes: A systematic review.
Muka T; Nano J; Voortman T; Braun KVE; Ligthart S; Stranges S; Bramer WM; Troup J; Chowdhury R; Dehghan A; Franco OH
Nutr Metab Cardiovasc Dis; 2016 Jul; 26(7):553-566. PubMed ID: 27146363
[TBL] [Abstract][Full Text] [Related]
15. Genetic and epigenetic mechanisms of NASH.
Eslam M; George J
Hepatol Int; 2016 May; 10(3):394-406. PubMed ID: 26683320
[TBL] [Abstract][Full Text] [Related]
16. Altered DNA Methylation Sites in Peripheral Blood Leukocytes from Patients with Simple Steatosis and Nonalcoholic Steatohepatitis (NASH).
Wu J; Zhang R; Shen F; Yang R; Zhou D; Cao H; Chen G; Pan Q; Fan J
Med Sci Monit; 2018 Oct; 24():6946-6967. PubMed ID: 30270343
[TBL] [Abstract][Full Text] [Related]
17. Genetics and epigenetics purpose in nonalcoholic fatty liver disease.
Botello-Manilla AE; Chávez-Tapia NC; Uribe M; Nuño-Lámbarri N
Expert Rev Gastroenterol Hepatol; 2020 Aug; 14(8):733-748. PubMed ID: 32552211
[TBL] [Abstract][Full Text] [Related]
18. Redox homeostasis and epigenetics in non-alcoholic fatty liver disease (NAFLD).
Podrini C; Borghesan M; Greco A; Pazienza V; Mazzoccoli G; Vinciguerra M
Curr Pharm Des; 2013; 19(15):2737-46. PubMed ID: 23092327
[TBL] [Abstract][Full Text] [Related]
19. Differential DNA methylation of steatosis and non-alcoholic fatty liver disease in adolescence.
Melton PE; Burton MA; Lillycrop KA; Godfrey KM; Rauschert S; Anderson D; Burdge GC; Mori TA; Beilin LJ; Ayonrinde OT; Craig JM; Olynyk JK; Holbrook JD; Pennell CE; Oddy WH; Moses EK; Adams LA; Huang RC
Hepatol Int; 2023 Jun; 17(3):584-594. PubMed ID: 36737504
[TBL] [Abstract][Full Text] [Related]
20. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis.
Pirola CJ; Fernández Gianotti T; Castaño GO; Mallardi P; San Martino J; Mora Gonzalez Lopez Ledesma M; Flichman D; Mirshahi F; Sanyal AJ; Sookoian S
Gut; 2015 May; 64(5):800-12. PubMed ID: 24973316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
